Alnylam Pharmaceuticals RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-definanzen.net GmbHhttp://images.finanzen.net/images/finanzen_net_neu.gifFinanzen.nethttp://www.finanzen.netSanofi-Aventis schließt Allianz mit Regulus Therapeuticshttp://www.finanzen.net/nachricht/aktien/Sanofi-Aventis-schliesst-Allianz-mit-Regulus-Therapeutics-814796Paris (aktiencheck.de AG) - Der franz&ouml;sische Pharmakonzern <a href="/aktien/Sanofi-Aventis-Aktie">Sanofi-Aventis</a> S.A. gab am Dienstag bekannt, dass er mit der amerikanischen Regulus Therapeutics Inc. eine strategische Allianz vereinbart hat.<!-- ...http://www.finanzen.net/nachricht/aktien/Sanofi-Aventis-schliesst-Allianz-mit-Regulus-Therapeutics-814796Alnylam Completes Key Technology Transfer Objectives in its Takeda Alliance and Earns $20 Million Paymenthttp://www.finanzen.net/nachricht/Alnylam-Completes-Key-Technology-Transfer-Objectives-in-its-Takeda-Alliance-and-Earns-20-Million-Payment-761237 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has earned a $20 million technology ...http://www.finanzen.net/nachricht/Alnylam-Completes-Key-Technology-Transfer-Objectives-in-its-Takeda-Alliance-and-Earns-20-Million-Payment-761237Alnylam and Collaborators Present New Pre-Clinical Research on RNAi Therapeutics Targeting PCSK9http://www.finanzen.net/nachricht/Alnylam-and-Collaborators-Present-New-Pre-Clinical-Research-on-RNAi-Therapeutics-Targeting-PCSK9-757085 <style type="text/css"> <!-- .bwlistitemmarginbottom {margin-bottom: 10.0px} .bwtextaligncenter {text-align: center} --> </style> <!-- sh_cad_1 --> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, ...http://www.finanzen.net/nachricht/Alnylam-and-Collaborators-Present-New-Pre-Clinical-Research-on-RNAi-Therapeutics-Targeting-PCSK9-757085Alnylam to Webcast Presentation at the 22nd Annual ROTH OC Growth Stock Conferencehttp://www.finanzen.net/nachricht/Alnylam-to-Webcast-Presentation-at-the-22nd-Annual-ROTH-OC-Growth-Stock-Conference-754738 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company ...http://www.finanzen.net/nachricht/Alnylam-to-Webcast-Presentation-at-the-22nd-Annual-ROTH-OC-Growth-Stock-Conference-754738Alnylam to Webcast Presentation at Cowen and Company’s 30th Annual Health Care Conferencehttp://www.finanzen.net/nachricht/Alnylam-to-Webcast-Presentation-at-Cowen-and-Company-s-30th-Annual-Health-Care-Conference-751554 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company ...http://www.finanzen.net/nachricht/Alnylam-to-Webcast-Presentation-at-Cowen-and-Company-s-30th-Annual-Health-Care-Conference-751554Alnylam Provides Update on Ongoing Litigation Regarding the Tuschl I Patent Serieshttp://www.finanzen.net/nachricht/Alnylam-Provides-Update-on-Ongoing-Litigation-Regarding-the-Tuschl-I-Patent-Series-751006 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the company and Max Planck have asked ...http://www.finanzen.net/nachricht/Alnylam-Provides-Update-on-Ongoing-Litigation-Regarding-the-Tuschl-I-Patent-Series-751006Alnylam to Webcast RNAi Roundtable on Thursday, March 4, 2010http://www.finanzen.net/nachricht/Alnylam-to-Webcast-RNAi-Roundtable-on-Thursday-March-4-2010-749109 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will be hosting a virtual RNAi ...http://www.finanzen.net/nachricht/Alnylam-to-Webcast-RNAi-Roundtable-on-Thursday-March-4-2010-749109Alnylam Pharmaceuticals Reports Fourth Quarter and 2009 Financial Resultshttp://www.finanzen.net/nachricht/Alnylam-Pharmaceuticals-Reports-Fourth-Quarter-and-2009-Financial-Results-748657 <style type="text/css"> <!-- .bwcellpaddingbottom1 {padding-bottom: 2.0px} .bwcellpaddingbottom3 {padding-bottom: 4.0px} .bwcellpaddingleft0 {padding-left: 0.0px} .bwcellpaddingright0 {padding-right: 0.0px} .bwcellparagraphmargin {margin-bottom: 0px; ...http://www.finanzen.net/nachricht/Alnylam-Pharmaceuticals-Reports-Fourth-Quarter-and-2009-Financial-Results-748657Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122http://www.finanzen.net/nachricht/Regulus-Therapeutics-and-GlaxoSmithKline-Establish-New-Collaboration-to-Develop-and-Commercialize-microRNA-Therapeutics-Targeting-miR-122-748276 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize ...http://www.finanzen.net/nachricht/Regulus-Therapeutics-and-GlaxoSmithKline-Establish-New-Collaboration-to-Develop-and-Commercialize-microRNA-Therapeutics-Targeting-miR-122-748276Alnylam Selected as One of the 50 Most Innovative Companies in the World by MIT’s Technology Reviewhttp://www.finanzen.net/nachricht/Alnylam-Selected-as-One-of-the-50-Most-Innovative-Companies-in-the-World-by-MIT-s-Technology-Review-747461 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has been selected as one of MIT ...http://www.finanzen.net/nachricht/Alnylam-Selected-as-One-of-the-50-Most-Innovative-Companies-in-the-World-by-MIT-s-Technology-Review-747461